Healthcare Organization
My healthcare organization is a large, urban academic medical hospital. We have a diverse patient population and a solid commitment to research and education. Our culture is one of collaboration and respect for each other’s expertise, which is fast-paced. The organization is constantly changing and evolving and is generally open to new ideas and approaches. There is a strong focus on evidence-based practice and a commitment to quality care. The organization is well-positioned to implement changes and has the resources and infrastructure to support new initiatives.
Practice Issue
There is a current problem with managing acute migraines as healthcare providers have insufficient information on the best practices to employ on Migraine patients. Many upcoming illnesses cause severe migraines. Patients require new medications that act as fats to relieve pain and have fewer side effects. The circumstances surrounding the need for change are that migraines are a debilitating condition that can significantly impact a person’s quality of life. Finding the medication that can provide long periods of relief from pain without having to ingest high dosages of drugs is a desired achievement in medical care. The scope of the issue is that migraines can be difficult to treat, and there is a lack of evidence-based treatments targeting the worst types of migraines. Moreover, the compatibility of pain medication with treatment for conditions causing migraines makes it more complicated to acquire the right medication.
The stakeholders involved are people who suffer from migraines, their families, and healthcare providers. Severe pain management requires collaboration from the various parties, who ensure a patient has the necessary resources and support to get proper treatment. The risks associated with change implementation include potential adverse side effects and the costs of new treatments.
Evidence-Based Idea
There is evidence to suggest that these techniques can be effective in the management of migraines. They are non-invasive and have few side effects. These techniques can be used alone or in combination with other treatments. Neuromodulation techniques, such as external trigeminal neurostimulation, can target specific brain areas that are believed to be involved in migraines. Erenumab is a monoclonal antibody that blocks the action of a protein that is thought to be involved in migraines. Mindfulness-based cognitive therapy is a form of therapy that can help patients to change their thinking patterns and reactions to stress. The risks associated with these techniques are generally low. However, as with any treatment, there is always the potential for side effects. The benefits of these techniques include the potential to reduce the frequency and severity of migraines and associated symptoms.
Plan for Knowledge Transfer
There are several ways to create and disseminate knowledge about these techniques. One way would be to develop educational materials, such as pamphlets or videos, that explain the methods and how they can be used to manage migraines. These materials can be distributed to patients, doctors, and insurance companies. Another way to disseminate knowledge about these techniques is to hold educational workshops or seminars. These can target specific audiences, such as doctors or insurance companies. There is also the potential to create an online course that can be taken by anyone interested in learning more about these techniques.
Once knowledge about these techniques has been created and disseminated, it is essential to encourage organizational adoption and implementation. One way to do this is to provide incentives, such as grants or financial incentives, to organizations that adopt and implement these techniques. Another way to encourage organizational adoption and implementation is to create standards or guidelines that recommend using these techniques.
Dissemination of Results
There are some ways to disseminate the results of the project. One way would be to publish the results in a peer-reviewed journal. This would allow other researchers to access the results and provide feedback. Another way to disseminate the results would be to present their results at a conference. This would allow for discussion and debate about the results. Additionally, the results could be disseminated through a website or blog. This would allow a broader audience to access the results.
Measurable Outcomes by Evidence-Based Change
The goal is to reduce the frequency and severity of migraines. This can be measured by tracking the number of migraines a patient experiences over time. Additionally, it is hoped that implementing these techniques will lead to fewer missed days of work or school. This can be measured by tracking the number of days a patient misses from work or school over a while. It is hoped that implementing these techniques will lead to fewer emergency room visits. This can be measured by tracking the number of emergency room visits. Finally, it is hoped that implementing these techniques will lead to lower costs associated with migraines. This can be measured by tracking the amount of money spent on medications, missed work, and emergency room visits.
Lessons Learnt
Summary of Articles
- A few key lessons can be learned from the summary of the article by Chou et al. (2019). External trigeminal neurostimulation (ETNS) is a new, promising treatment for acute migraine. ETNS is as effective as the standard treatment (sumatriptan) for acute migraine, with fewer side effects. 3. ETNS is a relatively unproven new treatment, and more research is needed to confirm its efficacy.
- Dodick et al. (2019) found that ubrogepant effectively treated migraines, with patients reporting a reduction in pain and disability. Ubrogepant was well-tolerated, with few patients reporting side effects. The study highlights the need for further research into using ubrogepant to treat migraines.
- Using neuromodulation techniques, such as transcranial electrical stimulation and transcranial magnetic stimulation, is effective for treating acute and preventive migraine (Moisset et al., 2020). Several different techniques can be used for neuromodulation, and the choice of method should be tailored to the individual patient.
- Erenumab is a safe and effective treatment for migraine. It is more effective than a placebo in reducing the number of migraine days. Moreover, it is well tolerated, with the most common side effects being injection site reactions and upper respiratory tract infections (Zhu et al., 2019)
- Mindfulness-based cognitive therapy (MBCT) can effectively treat migraine, reducing migraine-related disability in people with episodic and chronic migraine. MBCT may be more effective in reducing disability than other treatments, such as medication (Seng et al., 2019).
Critical Appraisal Tool
Based on the summary of the critical appraisal of the peer-reviewed articles, it can be concluded that neuromodulation techniques, such as occipital nerve stimulation (ONS) and remote electrical neuromodulation (REN), are effective for reducing the number of headache days per month in migraine sufferers. In addition, ubrogepant appears to be effective for acute migraine relief, although this medication’s long-term safety and efficacy are not yet known. Finally, mindfulness-based cognitive therapy for migraine (MBCT-M) is a promising intervention for reducing migraine-related disability.
The critical appraisal tool enabled the identification of sources useful to the goals intended by the research. Having the correct sources is essential to enrich a study with useful data that could be employed in clinical practice. Moreover, by analyzing the sources, the validity of the study is ascertained. For instance, the content of the studies proves the existence of the problem and offers various solutions to consider.
References
Chou, D. E., Shnayderman Yugrakh, M., Winegarner, D., Rowe, V., Kuruvilla, D., & Schoenen, J. (2019). Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia, 39(1), 3-14. Web.
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019). Ubrogepant for the treatment of migraine. New England Journal of Medicine, 381(23), 2230-2241. Web.
Gartley, C. E. (2019). Collaboration: The key to healthcare transformation. American Nurse. Web.
Moisset, X., Pereira, B., Ciampi de Andrade, D., Fontaine, D., Lantéri-Minet, M., & Mawet, J. (2020). Neuromodulation techniques for acute and preventive migraine treatment: A systematic review and meta-analysis of randomized controlled trials. The Journal of Headache and Pain, 21(1), 1-14. Web.
MediLexicon International. (n.d.). Migraines could be predicted with a new stress model. Medical News Today. Web.
Park, A. (2019). A new type of migraine drug targets pain during an attack. Time. Web.
Seng, E. K., Singer, A. B., Metts, C., Grinberg, A. S., Patel, Z. S., Marzouk, M., Rosenberg, L., Day, M., Minen, M. T., & Buse, D. C. (2019). Does mindfulness‐based cognitive therapy for migraine reduce migraine‐related disability in people with episodic and chronic migraine? A phase 2b pilot randomized clinical trial. Headache: The Journal of Head and Face Pain, 59(9), 1448-1467. Web.
Sponsored Content by AbbVieSep 26 2022Reviewed by Danielle Ellis. (2022). Designing a new treatment to treat migraine effectively. News. Web.
Zhu, C., Guan, J., Xiao, H., Luo, W., & Tong, R. (2019). Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials. Medicine, 98(52). 1-10. Web.